Livzon Pharmaceutical Group Inc. (000513.SZ) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-26). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. 000513.SZ files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.63% | 30.00% | Pass |
| Interest-bearing investments | 43.71% | 30.00% | Fail |
| Non-permissible income | 2.48% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.83% | 33.00% | Pass |
| Interest-bearing investments | 44.40% | 33.00% | Fail |
| Non-liquid assets | 46.22% | at least 20.00% | Pass |
| Non-permissible income | 2.48% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.83% | 33.33% | Pass |
| Cash + interest-bearing securities | 44.40% | 33.33% | Fail |
| Accounts receivable | 53.78% | 33.33% | Fail |
| Non-permissible income | 2.48% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.83% | 33.33% | Pass |
| Cash + interest-bearing securities | 44.40% | 33.33% | Fail |
| Accounts receivable | 53.78% | 50.00% | Fail |
| Non-permissible income | 2.48% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 10.04% | 33.00% | Pass |
| Cash + interest-bearing securities | 34.75% | 33.00% | Fail |
| Accounts receivable | 7.34% | 33.00% | Pass |
| Non-permissible income | 2.48% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 10.06% | 33.00% | Pass |
| Cash + interest-bearing securities | 34.81% | 49.00% | Pass |
| Accounts receivable | 7.35% | 49.00% | Pass |
| Non-permissible income | 2.48% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 10.06% | 33.33% | Pass |
| Cash + interest-bearing securities | 34.81% | 33.33% | Fail |
| Accounts receivable | 42.16% | 49.00% | Pass |
| Non-permissible income | 2.48% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 36.80 | NEUTRAL |
| Stochastic %K (14) | 54.44 | NEUTRAL |
| CCI (20) | -35.89 | NEUTRAL |
| Williams %R (14) | -45.56 | NEUTRAL |
| MACD (12,26,9) | 0.10 | BUY |
| ROC (10) | -0.15 | SELL |
| Momentum (10) | -0.04 | SELL |
| EMA (10) | 27.09 | SELL |
| SMA (10) | 26.88 | SELL |
| EMA (20) | 27.61 | SELL |
| SMA (20) | 27.49 | SELL |
| EMA (30) | 28.10 | SELL |
| SMA (30) | 28.53 | SELL |
| EMA (50) | 28.76 | SELL |
| SMA (50) | 29.41 | SELL |
| EMA (100) | 29.81 | SELL |
| SMA (100) | 29.70 | SELL |
| EMA (200) | 31.67 | SELL |
| SMA (200) | 31.60 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - Specialty & Generic
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neurological field; and shenqi fuzheng injection and anti-viral granules for the traditional Chinese medicine field. It also produces APIs and intermediates, such as mevastatin, acarbose, teicoplanin, gentamycin sulfate, phenylalanine, vancomycin hydrochloride, daptomycin, milbemycin oxime, and ceftriaxone sodium, as well as diagnostic reagents such as diagnostic kits for IgM antibody to mycoplasma pneumonia; diagnostic kits for human immunodeficiency virus antibody; and livzon antinuclear antibody test kits. In addition, the company offers nucleic acid test kits; livzon interferon-gamma release assays test kits; influenza A/B virus antigen detection kits; and treponema pallidum antibody detection kits. Further, it provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, stomatitis granules, biochemical and polypeptide APIs, and antibiotic APIs, as well as diagnostic equipment. Livzon Pharmaceutical Group Inc. was incorporated in 1985 and is headquartered in Zhuhai, China.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
